---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-23-000025"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2023-04-19T23:59:59+00:00"
generated_at: "2026-06-16T23:40:10.686581+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics appoints Alpna Seth, Ph.D., to board effective May 1, 2023

## Summary
- Board increased to eight members; Dr. Seth appointed as Class II director with term through 2025 annual meeting.
- Dr. Seth will serve on the Compensation Committee.
- Initial option grant of 20,000 shares vesting quarterly over three years; annual retainer $40,000 (board) plus $6,000 (committee).
- Dr. Seth previously CEO of Nura Bio, COO of Vir Biotechnology, and SVP at Biogen.

## SEC filing metadata
- accession: 0001664710-23-000025
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2023-04-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000025/0001664710-23-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000025/kros-20230413.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-23-000025
- JSON: https://secwatch.observer/filing/0001664710-23-000025.json
- Plain text: https://secwatch.observer/filing/0001664710-23-000025.txt

## Key facts
- Executive change
  Dr. Alpna Seth was appointed as director at Keros Therapeutics, Inc..
  - Action: appointed
  - Role: director
  source text: Dr. Alpna Seth as a director of the Company, effective on May 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000025/0001664710-23-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.